Fusion Pharmaceuticals Stock (NASDAQ:FUSN)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$21.52

52W Range

$2.31 - $21.60

50D Avg

$21.39

200D Avg

$10.42

Market Cap

$1.83B

Avg Vol (3M)

$1.97M

Beta

-0.69

Div Yield

-

FUSN Company Profile


Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

101

IPO Date

Jun 26, 2020

Website

FUSN Performance


FUSN Financial Summary


Dec 23Dec 22Dec 21
Revenue$2.07M$1.46M$1.44M
Operating Income$-99.23M$-88.03M$-82.02M
Net Income$-94.90M$-87.61M$-81.05M
EBITDA$-97.89M$-87.65M$-81.38M
Basic EPS$-1.45$-2.00$-1.90
Diluted EPS$-1.45$-2.00$-1.90

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
GRCLGracell Biotechnologies Inc.
OLMAOlema Pharmaceuticals, Inc.
PMVPPMV Pharmaceuticals, Inc.
IKNAIkena Oncology, Inc.
BCABBioAtla, Inc.
EWTXEdgewise Therapeutics, Inc.
SPROSpero Therapeutics, Inc.
RLMDRelmada Therapeutics, Inc.
FENCFennec Pharmaceuticals Inc.
JANXJanux Therapeutics, Inc.
PASGPassage Bio, Inc.
BOLTBolt Biotherapeutics, Inc.
KROSKeros Therapeutics, Inc.
HRMYHarmony Biosciences Holdings, Inc.
NAMSNewAmsterdam Pharma Company N.V.
NLTXNeurogene Inc.
CHRSCoherus BioSciences, Inc.
BCYCBicycle Therapeutics plc
RAPTRAPT Therapeutics, Inc.